转移性儿童甲状腺癌的遗传学特征和预后

doi:10.19401/j.cnki.1007-3639.2022.05.001

摘要/Abstract

摘要：

甲状腺癌的发病率随着年龄的增长而增加,虽然儿童甲状腺癌的发病率远低于成人,但在世界范围内甲状腺癌已经成为0~14岁儿童第5大常见癌症以及青少年最常见的癌症。不同于成人患者,目前普遍认为儿童甲状腺癌发病率的增加更有可能是基因或环境因素所致,并且儿童甲状腺癌在发病时往往更趋近于晚期,其复发率也远高于成人甲状腺癌,但是儿童甲状腺癌的分子病理学特征与肿瘤转移的关系仍有待进一步明确。本文将结合国内外研究进行综述,重点讨论转移性儿童甲状腺癌的遗传学特征,为研究者和临床医师针对儿童甲状腺癌的基础研究和肿瘤防治提供参考。

关键词: 儿童甲状腺癌, 肿瘤转移, 分子病理, 预后

Abstract:

The incidence rate of thyroid cancer increases with age. Although the incidence rate of thyroid cancer in children is far lower than in adults, thyroid cancer has become the fifth most common cancer among children aged 0-14 and the most common cancer among adolescents worldwide. Unlike thyroid cancer in adults, the increase in the incidence of thyroid cancer in children is more likely to be caused by genetic or environmental factors. Moreover, thyroid cancer in children tends to be late stage, and the recurrence rate is much higher than in adults. However, the relationship between molecular pathological characteristics and metastasis of thyroid cancer in children still needs to be further clarified. This review focused on the genetic changes of metastatic thyroid cancer in children in order to provide the reference for researchers and clinicians to better understand basic research, prevention and treatment of thyroid cancer in children.

Key words: Childhood thyroid carcinoma, Metastasis, Molecular pathology, Prognosis

中图分类号:

R736.1

曲以平, 侯鹏. 转移性儿童甲状腺癌的遗传学特征和预后[J]. 中国癌症杂志, 2022, 32(5): 373-379.

QU Yiping, HOU Peng. Genetic characteristics and prognosis of metastatic thyroid cancer in children[J]. China Oncology, 2022, 32(5): 373-379.

参考文献 63

[1]	PAULSON V A, RUDZINSKI E R, HAWKINS D S. Thyroid cancer in the pediatric population[J]. Genes, 2019, 10(9): 723. doi: 10.3390/genes10090723
[2]	HANLEY P, LORD K, BAUER A J. Thyroid disorders in children and adolescents: a review[J]. JAMA Pediatr, 2016, 170(10): 1008-1019. doi: 10.1001/jamapediatrics.2016.0486
[3]	BAUER A J. Pediatric thyroid cancer: genetics, therapeutics and outcome[J]. Endocrinol Metab Clin North Am, 2020, 49(4): 589-611. doi: 10.1016/j.ecl.2020.08.001
[4]	LUZÓN-TORO B, FERNÁNDEZ R, VILLALBA-BENITO L, et al. Influencers on thyroid cancer onset: molecular genetic basis[J]. Genes, 2019, 10(11): 913. doi: 10.3390/genes10110913
[5]	CHAN C M, YOUNG J, PRAGER J, et al. Pediatric thyroid cancer[J]. Adv Pediatr, 2017, 64(1): 171-190. doi: 10.1016/j.yapd.2017.03.007
[6]	PARISI M T, KHALATBARI H, PARIKH S R, et al. Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach[J]. Pediatr Radiol, 2019, 49(11): 1391-1403. doi: 10.1007/s00247-019-04457-7
[7]	CHESOVER A D, VALI R, HEMMATI S H, et al. Lung metastasis in children with differentiated thyroid cancer: factors associated with diagnosis and outcomes of therapy[J]. Thyroid, 2021, 31(1): 50-60. doi: 10.1089/thy.2020.0002
[8]	KIRATLI P O, VOLKAN-SALANCI B, GÜNAY E C, et al. Thyroid cancer in pediatric age group: an institutional experience and review of the literature[J]. J Pediatr Hematol Oncol, 2013, 35(2): 93-97. doi: 10.1097/MPH.0b013e3182755d9e
[9]	DERMODY S, WALLS A, HARLEY E H Jr. Pediatric thyroid cancer: an update from the SEER database 2007-2012[J]. Int J Pediatr Otorhinolaryngol, 2016, 89: 121-126. doi: 10.1016/j.ijporl.2016.08.005
[10]	CHRISTISON-LAGAY E, BAERTSCHIGER R M. Management of differentiated thyroid carcinoma in pediatric patients[J]. Surg Oncol Clin N Am, 2021, 30(2): 235-251. doi: 10.1016/j.soc.2020.11.013
[11]	LEE Y A, JUNG H W, KIM H Y, et al. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years[J]. J Clin Endocrinol Metab, 2015, 100(4): 1619-1629. doi: 10.1210/jc.2014-3647
[12]	CORDIOLI M I, MORAES L, CURY A N, et al. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma?[J]. Endocr Relat Cancer, 2015, 22(6): R311-R324. doi: 10.1530/ERC-15-0381
[13]	O’GORMAN C S, HAMILTON J, RACHMIEL M, et al. Thyroid cancer in childhood: a retrospective review of childhood course[J]. Thyroid, 2010, 20(4): 375-380. doi: 10.1089/thy.2009.0386
[14]	NIKIFOROV Y E. Radiation-induced thyroid cancer: what we have learned from Chernobyl[J]. Endocr Pathol, 2006, 17(4): 307-317. doi: 10.1007/s12022-006-0001-5
[15]	FEINMESSER R, LUBIN E, SEGAL K, et al. Carcinoma of the thyroid in children: a review[J]. J Pediatr Endocrinol Metab, 1997, 10(6): 561-568.
[16]	AL-QURAYSHI Z, HAUCH A, SRIVASTAV S, et al. A national perspective of the risk, presentation, and outcomes of pediatric thyroid cancer[J]. JAMA Otolaryngol Head Neck Surg, 2016, 142(5): 472-478. doi: 10.1001/jamaoto.2016.0104
[17]	RUSSO M, MALANDRINO P, MOLETI M, et al. Differentiated thyroid cancer in children: heterogeneity of predictive risk factors[J]. Pediatr Blood Cancer, 2018, 65(9): e27226. doi: 10.1002/pbc.27226
[18]	NGO D Q, LE D T, NGO Q X, et al. Risk factors for lateral lymph node metastasis of papillary thyroid carcinoma in children[J]. J Pediatr Surg, 2022
[19]	BAUMGARTEN H, JENKS C M, ISAZA A, et al. Bilateral papillary thyroid cancer in children: risk factors and frequency of postoperative diagnosis[J]. J Pediatr Surg, 2020, 55(6): 1117-1122. doi: 10.1016/j.jpedsurg.2020.02.040
[20]	NGO D Q, NGO Q X, VAN LE Q. Pediatric thyroid cancer: risk factors for central lymph node metastasis in patients with cN₀ papillary carcinoma[J]. Int J Pediatr Otorhinolaryngol, 2020, 133: 110000. doi: 10.1016/j.ijporl.2020.110000
[21]	RUBINSTEIN J C, HERRICK-REYNOLDS K, DINAUER C, et al. Recurrence and complications in pediatric and adolescent papillary thyroid cancer in a high-volume practice[J]. J Surg Res, 2020, 249: 58-66. doi: 10.1016/j.jss.2019.12.002
[22]	KIM J, SUN Z F, ADAM M A, et al. Predictors of nodal metastasis in pediatric differentiated thyroid cancer[J]. J Pediatr Surg, 2017, 52(1): 120-123. doi: 10.1016/j.jpedsurg.2016.10.033
[23]	LIU Z M, HU D, HUANG Y H, et al. Factors associated with distant metastasis in pediatric thyroid cancer: evaluation of the SEER database[J]. Endocr Connect, 2019, 8(2): 78-85. doi: 10.1530/EC-18-0441
[24]	SHUKLA N, OSAZUWA-PETERS N, MEGWALU U C. Association between age and nodal metastasis in papillary thyroid carcinoma[J]. Otolaryngol Head Neck Surg, 2021, 165(1): 43-49. doi: 10.1177/0194599820966995
[25]	TANG A L, KLOOS R T, AUNINS B, et al. Pathologic features associated with molecular subtypes of well-differentiated thyroid cancer[J]. Endocr Pract, 2021, 27(3): 206-211. doi: 10.1016/j.eprac.2020.09.003
[26]	GALUPPINI F, VIANELLO F, CENSI S, et al. Differentiated thyroid carcinoma in pediatric age: genetic and clinical scenario[J]. Front Endocrinol (Lausanne), 2019, 10: 552. doi: 10.3389/fendo.2019.00552
[27]	IWADATE M, MITSUTAKE N, MATSUSE M, et al. The clinicopathological results of thyroid cancer with BRAF V600E mutation in the young population of fukushima[J]. J Clin Endocrinol Metab, 2020, 105(12): dgaa573.
[28]	DECAUSSIN-PETRUCCI M, DELADOËY J, HAFDI-NEJJARI Z, et al. Expression of CD133 in differentiated thyroid cancer of young patients[J]. J Clin Pathol, 2015, 68(6): 434-440. doi: 10.1136/jclinpath-2014-202625
[29]	CORDIOLI M I C V, MORAES L, CARVALHEIRA G, et al. AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma[J]. Cancer Med, 2016, 5(7): 1535-1541. doi: 10.1002/cam4.698
[30]	ALZAHRANI A S, ALSWAILEM M, ALSWAILEM A A, et al. Genetic alterations in pediatric thyroid cancer using a comprehensive childhood cancer gene panel[J]. J Clin Endocrinol Metab, 2020, 105(10): dgaa389.
[31]	ELISEI R, ROMEI C, VORONTSOVA T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults[J]. J Clin Endocrinol Metab, 2001, 86(7): 3211-3216.
[32]	ZEINDL-EBERHART E, LIEBMANN S, JUNGBLUT P R, et al. Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species[J]. Amino Acids, 2011, 41(2): 415-425. doi: 10.1007/s00726-010-0733-x
[33]	MOSTOUFI-MOAB S, LABOURIER E, SULLIVAN L, et al. Molecular testing for oncogenic gene alterations in pediatric thyroid lesions[J]. Thyroid, 2018, 28(1): 60-67. doi: 10.1089/thy.2017.0059
[34]	FRANCO A T, RICARTE-FILHO J C, ISAZA A, et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers[J]. J Clin Oncol, 2022, 40(10): 1081-1090.
[35]	SASSOLAS G, HAFDI-NEJJARI Z, FERRARO A, et al. Oncogenic alterations in papillary thyroid cancers of young patients[J]. Thyroid, 2012, 22(1): 17-26. doi: 10.1089/thy.2011.0215
[36]	OISHI N, KONDO T, NAKAZAWA T, et al. Frequent BRAF V600E and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan[J]. Endocr Pathol, 2017, 28(2): 103-111. doi: 10.1007/s12022-017-9470-y
[37]	ONDER S, OZTURK SARI S, YEGEN G, et al. Classic architecture with multicentricity and local recurrence, and absence of TERT promoter mutations are correlates of BRAF (V600E) harboring pediatric papillary thyroid carcinomas[J]. Endocr Pathol, 2016, 27(2): 153-161. doi: 10.1007/s12022-016-9420-0
[38]	OTSUBO R, MUSSAZHANOVA Z, AKAZAWA Y, et al. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature[J]. J Pediatr Endocrinol Metab, 2018, 31(4): 461-467. doi: 10.1515/jpem-2017-0292
[39]	SCOUTEN W T, PATEL A, TERRELL R, et al. Cytoplasmic localization of the paired box gene, Pax-8, is found in pediatric thyroid cancer and may be associated with a greater risk of recurrence[J]. Thyroid, 2004, 14(12): 1037-1046. doi: 10.1089/thy.2004.14.1037
[40]	STOSIC A, FULIGNI F, ANDERSON N D, et al. Diverse oncogenic fusions and distinct gene expression patterns define the genomic landscape of pediatric papillary thyroid carcinoma[J]. Cancer Res, 2021, 81(22): 5625-5637. doi: 10.1158/0008-5472.CAN-21-0761
[41]	FRANCO A T, LABOURIER E, ABLORDEPPEY K K, et al. miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing[J]. Pediatr Blood Cancer, 2020, 67(6): e28276.
[42]	ELOY C, SANTOS J, SOARES P, et al. Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma[J]. Virchows Arch, 2011, 459(6): 595-605. doi: 10.1007/s00428-011-1161-3
[43]	SHIMURA K, SHIBATA H, MIZUNO Y, et al. Rapid growth and early metastasis of papillary thyroid carcinoma in an adolescent girl with Graves' disease[J]. Horm Res Paediatr, 2019, 91(3): 210-215. doi: 10.1159/000491102
[44]	CORDIOLI M I C V, MORAES L, ALVES M T, et al. Thyroid-specific genes expression uncovered age-related differences in pediatric thyroid carcinomas[J]. Int J Endocrinol, 2016, 2016: 1956740.
[45]	JARZAB B, HANDKIEWICZ-JUNAK D. Differentiated thyroid cancer in children and adults: same or distinct disease?[J]. Hormones (Athens), 2007, 6(3): 200-209.
[46]	LAN X B, BAO H, GE X Y, et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis[J]. Cancer Sci, 2020, 111(6): 2163-2173. doi: 10.1111/cas.14389
[47]	ZANELLA A B, SCHEFFEL R S, NAVA C F, et al. Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer[J]. Thyroid, 2018, 28(10): 1285-1292. doi: 10.1089/thy.2018.0075
[48]	NIKIFOROV Y E. Thyroid carcinoma: molecular pathways and therapeutic targets[J]. Mod Pathol, 2008, 21(Suppl 2): S37-S43. doi: 10.1038/modpathol.2008.10
[49]	DINAUER C A, BREUER C, RIVKEES S A. Differentiated thyroid cancer in children: diagnosis and management[J]. Curr Opin Oncol, 2008, 20(1): 59-65. doi: 10.1097/CCO.0b013e3282f30220
[50]	FRANCIS G L, WAGUESPACK S G, BAUER A J, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2015, 25(7): 716-759. doi: 10.1089/thy.2014.0460
[51]	SUBBIAH V, HU M I, WIRTH L J, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8): 491-501. doi: 10.1016/S2213-8587(21)00120-0
[52]	BRADFORD D, LARKINS E, MUSHTI S L, et al. FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions[J]. Clin Cancer Res, 2021, 27(8): 2130-2135. doi: 10.1158/1078-0432.CCR-20-3558
[53]	BROSE M S, NUTTING C M, JARZAB B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319-328. doi: 10.1016/S0140-6736(14)60421-9
[54]	FENG G L, LUO Y, ZHANG Q, et al. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis[J]. Endocrine, 2020, 68(1): 56-63. doi: 10.1007/s12020-019-02167-6
[55]	HIGUCHI Y, MOTOKI T, ISHIDA H, et al. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report[J]. BMC Cancer, 2017, 17(1): 775. doi: 10.1186/s12885-017-3782-7
[56]	WELLS S A Jr, ROBINSON B G, GAGEL R F, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(2): 134-141.
[57]	GRANDE E, KREISSL M C, FILETTI S, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies[J]. Adv Ther, 2013, 30(11): 945-966. doi: 10.1007/s12325-013-0069-5
[58]	FOX E, WIDEMANN B C, CHUK M K, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma[J]. Clin Cancer Res, 2013, 19(15): 4239-4248. doi: 10.1158/1078-0432.CCR-13-0071
[59]	FERRARI S M, ELIA G, RAGUSA F, et al. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer[J]. Expert Opin Investig Drugs, 2021, 30(9): 913-921. doi: 10.1080/13543784.2021.1972971
[60]	MATRONE A, PRETE A, NERVO A, et al. Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer[J]. J Endocrinol Invest, 2021, 44(10): 2139-2151. doi: 10.1007/s40618-020-01491-3
[61]	MAHAJAN P, DAWRANT J, KHERADPOUR A, et al. Response to lenvatinib in children with papillary thyroid carcinoma[J]. Thyroid, 2018, 28(11): 1450-1454. doi: 10.1089/thy.2018.0064
[62]	GASPAR N, CAMPBELL-HEWSON Q, MELCON S G, et al. Phase Ⅰ/Ⅱ study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)[J]. ESMO Open, 2021, 6(5): 100250. doi: 10.1016/j.esmoop.2021.100250
[63]	ZHANG Y C, DENG X Z, DING Z, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: a case report[J]. Medicine, 2021, 100(12): e25191. doi: 10.1097/MD.0000000000025191